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Although palmitoylation regulates numerous cellular processes, as yet efforts to manipulate
this post-translational modification for therapeutic gain have proved unsuccessful. The Na-
pump accessory sub-unit phospholemman (PLM) is palmitoylated by zDHHC5. Here, we
show that PLM palmitoylation is facilitated by recruitment of the Na-pump α sub-unit to a
specific site on zDHHC5 that contains a juxtamembrane amphipathic helix. Site-specific
palmitoylation and GlcNAcylation of this helix increased binding between the Na-pump and
zDHHC5, promoting PLM palmitoylation. In contrast, disruption of the zDHHC5-Na-pump
interaction with a cell penetrating peptide reduced PLM palmitoylation. Our results suggest
that by manipulating the recruitment of specific substrates to particular zDHHC-palmitoyl
acyl transferases, the palmitoylation status of individual proteins can be selectively altered,
thus opening the door to the development of molecular modulators of protein palmitoylation
for the treatment of disease.
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Palmitoylation is the reversible attachment of the fatty acidpalmitate to cysteine thiols via a thioester bond1. Manydifferent classes of protein are palmitoylated, including G-
proteins2–4, ion channels, transporters and their regulators5–7,
receptors8, as well as kinases9,10. Palmitoylation induces sub-
stantial changes in the secondary structure and therefore function
of intracellular regions of target proteins through their recruit-
ment to the surface of a membrane bilayer via the palmitoylated
cysteine. Since palmitoylation dynamically and directly regulates
the localization, interactions, turnover, and activity of numerous
classes of protein7,11–14, and can have a profound impact on the
landscape of the plasma membrane15,16, manipulation of protein
palmitoylation with, for example, small molecules has the
potential to exert substantial changes to cellular function.
Protein palmitoylation is catalyzed by a family of zinc finger
and DHHC motif containing palmitoyl acyltransferase enzymes
(zDHHC-PATs), reversed by protein thioesterases, and occurs
dynamically and reversibly throughout the secretory pathway in a
manner analogous to phosphorylation17. zDHHC-PATs are
characterized by a cysteine-rich region with a conserved Asp-His-
His-Cys (DHHC) motif17 within the active site18; there are 23
human isoforms. They typically have four transmembrane (TM)
domains, with a conserved ca. 50 amino acid cytosolic core
between TM2 and 3 containing the zDHHC motif. In contrast,
the intracellular amino and carboxyl termini are poorly con-
served, and contribute to zDHHC isoform substrate selectivity17.
The acyltransferase zDHHC5 is primarily located at the cell
surface19 where it regulates a diverse range of physiological
processes. Known zDHHC5 substrates include somatostatin
receptor 520, sphingosine-1-phosphate receptor 121, the lipid raft
protein flotillin 222, the Na-pump regulatory protein phospho-
lemman (PLM)7,13, desmoglein-2 and plakophilin-323 as well as
the neuronal proteins δ-catenin24 and GRIP 125.
Unlike kinases, for which there are an ever-increasing number
of inhibitors approved for use in the clinic26,27, no therapeutically
useful molecular modulators of protein palmitoylation have been
developed thus far. This, in no small part, is due to a fundamental
lack of knowledge regarding the molecular basis of both enzyme
catalysis and substrate recruitment by zDHHC-PATs. To date,
efforts to discover inhibitors of zDHHC-PATs have largely
focussed on the enzyme’s active site targeting catalytic activity
(e.g.,28–30). However, the palmitoylation status of specific proteins
may also be changed by selectively manipulating their recruit-
ment to (a) cognate zDHHC-PAT(s).
The ubiquitous Na-K ATPase (Na-pump) is a P-type ATPase
and is located at the surface of eukaryotic cells where it carries out
the active export of 3 sodium (Na) and import of 2 potassium (K)
ions per catalytic cycle across the plasma membrane. The Na
pump is a multisubunit enzyme complex comprising an α (cat-
alytic core of the enzyme that contains the Na, K and ATP
binding sites), a β (required for trafficking of the Na pump
through the secretory pathway) and a FXYD (regulates the kinetic
properties and/or substrate affinities of the Na-pump) sub-unit31.
PLM (FXYD1) regulates the Na-pump in muscle by way of post-
translational modifications to its cytosolic C tail. PLM phos-
phorylation activates and PLM palmitoylation inhibits the Na-
pump31,32. The Na-pump is not the only P-type ATPase regu-
lated by a small palmitoylated accessory sub-unit. The SERCA 2a
regulators phospholamban33 and sarcolipin34 are both palmi-
toylated within their transmembrane domains suggesting that
palmitoylation may play an important general role in regulating
P-type ATPase activity.
Previously, we have shown in cardiac muscle that the Na-pump
interacts with zDHHC5 in a region immediately following
transmembrane domain 4 (αα 218–334) and that this contact is
required for palmitoylation of PLM13. Here, we show that PLM
palmitoylation can be altered by manipulating the interaction
between zDHHC5 and the Na-pump α sub-unit via post-
translational modifications (palmitoylation, GlcNacylation) to
zDHHC5 as well as with a pharmacological tool. In short, we
show that the palmitoylation status of a specific substrate protein
can be modified through controlling its interaction with a partner
zDHHC-PAT.
Results
Mapping the Na-pump binding site on zDHHC5. Previously,
we have shown by truncation analysis that a region on zDHHC5
located between N218 and T334 is required for Na-pump binding
and PLM palmitoylation13. The position of the binding site of the
Na-pump on zDHHC5 was determined more exactly here by
purifying the Na-pump from detergent-solubilized rat ventricular
homogenates with an array of overlapping biotinylated 25mer
peptides that covered the acyltransferase region αα 218–334.
Western Blot analysis revealed a Na-pump binding peak com-
prising three overlapping peptides with the αα 233–257 peptide
(termed Na-pump binding site peptide (NBSP)) displaying
highest levels of pulldown (Fig. 1a). To gain insights into the
tertiary position of the Na-pump binding site on zDHHC5, the
primary sequence of the zDHHC5 C-terminal domain was
compared with that of zDHHC20 whose crystal structure has
recently been reported35 aligning the sequences at the highly
conserved TTxE motif (Fig. 1b). zDHHC5 and 20 have appreci-
able homology (40% identity, 73% similarity) across their pal-
mitoyltransferase conserved C-terminus (PaCCT) motifs36
suggesting that they likely have similar structures in this region.
The zDHHC20 PaCCT motif contains an amphipathic helix (αα
264–271)35 which is conserved in zDHHC5 (αα 237–244) also
(Fig. 1c). The NBSP contains the amphipathic helix in its entirety
suggesting that this structural feature may be important for
binding between zDHHC5 and the Na-pump. The amphipathic
helix is flanked at its N-terminus by two cysteine residues (C236,
C237) (Fig. 1d), both of which have previously been shown to be
palmitoylated37. The proximity of these modifiable residues to the
Na-pump binding site on zDHHC5 suggested to us that Na-
pump recruitment to zDHHC5 may be regulated by post-
translational modification. Surprisingly, the position of the
Na-pump binding site on zDHHC5 was to be found a con-
siderable distance from the enzyme active site (Fig. 1e), suggesting
that this region of the acyltransferase does not interact directly
with PLM.
zDHHC5 interacts with the Na-pump α-sub-unit. The inter-
action between zDHHC5 and the Na-pump occurs in the cyto-
sol13. To address whether or not zDHHC5 interacts with PLM
directly or via one of the other (α, β) pump subunits, a series of
biotinylated peptides covering the PLM intracellular C-tail were
tested for their ability to purify HA-tagged zDHHC5 from HEK
cells. zDHHC5 could not be purified with any of the peptides
including one comprising the entire PLM C-tail (Fig. 2a). How-
ever, the PLM peptides all purified the Na-pump α subunit as
expected demonstrating that the pulldown experiment had been
successful (Fig. 2a). Together, these results confirm that PLM and
zDHHC5 do not interact directly.
To establish which Na-pump sub-unit zDHHC5 interacts with,
the NBSP was used to purify the Na-pump from whole rat heart
lysates either as an intact complex or as individual subunits
following dissociation of the pump using harsh detergents. Whole
rat heart homogenate was lysed with four different detergents
(C12E10, Triton, SDS, and FC-12) and each lysate divided in
two. Biotinylated NBSP was added to one half of each lysate
and binding partners captured with streptavidin sepharose beads.
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An antibody specific to PLM phosphorylated at serine 68 (which
captures PLM as part of the Na-pump complex38) was added to
the other half of each lysate, and interacting proteins purified
using protein G sepharose beads. The Na-pump α subunit could
only be co-immunoprecipitated with (phospho-S68)PLM from
the C12E10 lysate suggesting that Triton, SDS, and FC-12 had
caused dissociation of the Na-pump oligomer into individual
subunits, potentially in a partial or fully denatured state (Fig. 2b).
The NBSP purified the pump α subunit but not PLM from the
FC-12 lysate suggesting that zDHHC5 interaction with the Na-
pump is independent of the presence of PLM, and is likely
through a direct interaction with the α subunit (Fig. 2b).
Fig. 1 Identification of the Na-pump binding site on zDHHC5. a The Na-pump was purified from rat ventricular lysate using an array of overlapping
peptides covering zDHHC5 region αα 218–334. A binding peak comprising three overlapping peptides centered on peptide αα 233–257, the Na-pump
binding site peptide (NBSP), was observed. b Alignment of the zDHHC5 and 20 C-terminal domains in the region of their TTxE and PaACT motifs. c The
PaACT motifs of both zDHHC5 and 20 contain an amphipathic helix (red, non-polar; purple, polar). d Structural model of the NBSP based on the structure
of zDHHC20 (PDB accession code 6BML) with putative sites of post-translational modification shown (palmitoylation, yellow; GlcNAcylation, green).
e The position of the NBSP (blue) on the structure of zDHHC20 (PDB 6BML). The NBSP is located a considerable distance from the enzyme active site
(C of zDHHC motif, pink; 2-bromopalmitate, red) suggesting that the interaction between zDHHC5 and PLM is likely to be indirect. Figure 1d, e were made
using MacPYMOL.
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We sought to identify the region of the Na-pump α sub-unit
that interacts with zDHHC5. Co-expression of zDHHC5 with the
third intracellular loop of the pump α1 sub-unit (IL3) in HEK
cells resulted in a significant stabilization of IL3 (human isoform:
αα 339–772) (Fig. 2c) which suggests that zDHHC5 and IL3
interact. Furthermore, GST-tagged recombinant IL3 but not GST
alone nor GST fused to the fourth intracellular loop of the α
subunit (GST-IL4 (αα 824–843)) purified HA-tagged zDHHC5
from a HEK cell lysate (Fig. 2d). We conclude that IL3 is the
region of the Na-pump α subunit that interacts with zDHHC5.
zDHHC5 acylation by zDHHC20 regulates Na-pump recruit-
ment. The region of zDHHC5 that interacts with the Na-pump
contains three cysteine residues located at positions 236, 237, and
245. To determine whether or not these cysteines are acylated,
their palmitoylation status in HEK cells was investigated by both
resin-assisted capture of acylated proteins (acyl RAC, which
affinity purifies palmitoylated proteins)39 and acyl PEG exchange
(APE, which exchanges palmitate for a 5 kDa PEG molecule and
hence induces a band shift on SDS-PAGE)13,40. As the catalytic
cysteine in zDHHC-PATs is transiently palmitoylated during the
reaction cycle18, and acyl RAC purifies palmitoylated proteins
regardless of whether they are singly or multiply palmitoylated,
the palmitoylation of catalytically inactive zDHHS5 (C134S) was
assessed. zDHHS5 is robustly palmitoylated in HEK cells
(Fig. 3a). Mutation of cysteines 236 and 237 to alanine, however,
largely abolished zDHHS5 palmitoylation indicating that either
and/or both residues are modified. Mutation of cysteine 245 was
essentially without effect, suggesting that this residue is not pal-
mitoylated. We suggest that the residual palmitoylation observed
with zDHHS5 C236A/C237A reflects palmitoylation of zDHHC5
in its cysteine-rich domain similar to that which occurs in other
zDHHC enzymes41. Acyl PEG exchange revealed that zDHHC5,
zDHHS5, C236A/C237A zDHHS5, and C245A zDHHS5 had 3, 2,
1, and 2 palmitoylated cysteines in HEK cells respectively, sug-
gesting that either C-236 or C-237 is palmitoylated (Fig. 3b).
Mutation of C236 and C237 to alanine also reduced co-
immunoprecipitation between zDHHC5 and the Na-pump
(Fig. 3c), suggesting that the presence of a membrane anchor in
this part of zDHHC5 contributes to its interaction with the Na-
pump.
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Fig. 2 zDHHC5 interacts with intracellular loop 3 of the Na-pump α-sub-unit. a A series of peptides covering the PLM C-tail successfully purified
endogenous Na-pump α sub-unit but not zDHHC5 from rat ventricular myocyte lysate. b Whole rat heart homogenate was lysed with four different
detergents (C12E10, Triton X-100, SDS, and FC-12). Each lysate was split in half and two separate purifications performed using the NBSP or an antibody
specific to PLM phosphorylated at serine 68. c Co-expression of HA-zDHHC5 in FT-293 cells stably expressing human PLM caused an increase in FLAG-
IL3 accumulation compared to when FLAG-IL3 was expressed alone (n= 5: **p < 0.01). d HA-tagged zDHHC5 can be purified from a HEK cell lysate using
recombinant GST-IL3 but not GST alone or GST-IL4.
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To determine whether the dicysteine motif is palmitoylated by
endogenous zDHHC5 or another upstream zDHHC-PAT, the
palmitoylation status of HA-tagged zDHHS5 in wild type and
zDHHC5 knockout (Fig. 3d) HEK cells was determined. The
catalytically inactive enzyme had essentially identical palmitoyla-
tion in both cell lines, suggesting that the zDHHC5 dicysteine
motif is palmitoylated by an enzyme other than zDHHC5
(Fig. 3e). To identify the zDHHC-PAT responsible we used a
proximity biotinylation approach. This employs a mutant
(R188G) form of the bacterial biotin ligase BirA that releases a
highly reactive, labile reaction intermediate which biotinylates
primary amines on nearby (interacting) proteins42. We generated
fusion proteins with BirA fused at either the intracellular N or C
terminus of zDHHC5, and biotinylated proteins interacting with
the zDHHC5-BirA fusions (or BirA alone) in HEK cells identified
by LC-MS/MS following their purification with streptavidin beads
(Supplementary Data 1). The only zDHHC-PAT found to
interact with zDHHC5 was zDHHC20 (Supplementary Data 2).
Overexpression of HA-tagged zDHHC20 (Fig. 3f) but not
DHHS20 (Fig. 3g) caused increased palmitoylation of the
zDHHS5 C-tail. Furthermore, zDHHC20 overexpression also
caused increased co-immunoprecipitation of zDHHC5 with the
Na-pump in HEK cells (Fig. 3h). Hence, zDHHC20 palmitoylates
zDHHC5 at C236/7, regulating the interaction between zDHHC5
and the Na-pump, controlling PLM palmitoylation.
zDHHC5 O-GlcNAcylation regulates PLM palmitoylation. O-
GlcNAcylation—the attachment of O-linked N-acetylglucosamine
(O-GlcNAc) sugar groups to intracellular proteins—is a critically
important post-translational modification that regulates a wide
range of cellular processes in metazoans43. The reversible
attachment of O-GlcNAc to specific serine and threonine residues
in particular substrate proteins is carried out by a single pair of
enzymes, called O‑GlcNAc transferase (OGT) and O‑GlcNAcase
(OGA). Using proximity biotinylation we found that OGT
interacts with both BirA-zDHHC5 and zDHHC5-BirA in the
cardiomyoblast cell line H9c2 (Supplementary Data 3). In
zDHHC5, S241 is located on the hydrophilic face of the amphi-
pathic helix (Fig. 1d), and fits the OGT consensus sequence
(relative to the GlcNAcylated serine position −1, V; +1, R44).
OGT substrates are typically disordered on the C terminal side of
the GlcNAcylation site44; the zDHHC5 C tail is predicted to be
disordered13,45. This suggested to us that GlcNAcylation may
regulate Na-pump recruitment to and PLM palmitoylation by
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Fig. 3 Na-pump recruitment to zDHHC5 can be regulated by
palmitoylation. a HEK 293 cells were transiently transfected to express
WT DHHC5 or catalytically inactive DHHS5 +/− C236A/C237A, (AA),
C245A, (A) or C236A/C237A/C245A, (AAA) mutants. Palmitoylated
fractions were purified by resin-assisted capture (Acyl-RAC) and visualized
by Western Blot. The average data is shown in graph form with
palmitoylation expressed as the ratio of Palmitoylated (Palm)/
Unfractionated (UF) zDHHC/S5 (n= 3: *p < 0.05, **p < 0.01). b The
number of sites palmitoylated in zDHHC5, zDHHS5, and three zDHHS5 C-
tail mutants (236/7AA, 245A and 236/7–245AAA) was determined by
Acyl PEG exchange. c Co-immunoprecipitation of HA-tagged zDHHC5 and
236/7AA mutant with PLM. The amount of PLM co-immunoprecipitated
was expressed relative to the amount of zDHHC5 immunoprecipitated
(n= 3: ****p < 0.0001). d HEK 293 cells were engineered with CRISPR/
Cas9 to create a zDHHC5 knockout cell line (zDHHC5 KO). zDHHC5 can
be reintroduced to the KO cells by transient transfection. e Both HEK 293
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0.05, **p < 0.01). g Impact of wild type and catalytically inactive zDHHC20
on the palmitoylation status of zDHHS5 (n= 4: *p < 0.05, **p < 0.01).
h HA-tagged WT zDHHC5 and the C236/7AA mutant were expressed in
HEK 293 cells +/− zDHHC20 and immunoprecipitated with HA beads.
Associated PLM was visualized by Western Blotting.
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zDHHC5, and this possibility was considered in a series of
experiments. zDHHC5 could be purified with recombinant Halo-
tagged catalytically inactive OGA demonstrating that the acyl-
transferase is GlcNAcylated in both rat hearts and transfected
HEK cells (Fig. 4a). Treatment of a FT-293 stable cell line
expressing PLM with the OGA inhibitor GlcNAc-statin (GNS)
increased both PLM palmitoylation and co-immunoprecipitation
between zDHHC5 and the Na-pump in cells transfected with
wild-type zDHHC5 but not a S241A mutant (Fig. 4b, c). Toge-
ther, this suggests that GlcNAcylation of zDHHC5 S241 pro-
motes PLM palmitoylation through increased recruitment of the
Na-pump to zDHHC5.
Pharmacological manipulation of PLM palmitoylation. Site-
specific palmitoylation and GlcNAcylation of zDHHC5 promotes
PLM palmitoylation through increased recruitment of the Na-
pump to the acyltransferase. Next, we wanted to ascertain
whether or not PLM palmitoylation could be reduced with a
pharmacological tool by blocking the interaction between
zDHHC5 and the Na-pump. HEK cells stably expressing human
PLM were incubated with a cell-penetrating stearate-tagged version
of NBSP. Following both 3 and 24 h treatments, PLM palmitoy-
lation was significantly reduced in cells treated with stearate-tagged
NBSP compared to an equivalent scrambled control (Fig. 5a). In
contrast, the disruptor peptide had no effect on H-ras palmitoy-
lation, which was expected as H-ras is a substrate for zDHHC946.
The disruptor peptide also reduced the palmitoylation of endo-
genous PLM but not Caveolin-3 in rat ventricular myocytes
(Fig. 5b). In short, our results suggest that PLM palmitoylation can
be selectively reduced using a pharmacological tool that prevents
the Na-pump from interacting with zDHHC5.
Discussion
Although protein S-palmitoylation is a critical regulator of cel-
lular function, the molecular mechanism by which substrates are
recognized and enzyme catalysis occurs is only poorly under-
stood. Here, we have identified a discrete binding site on
zDHHC5 for the Na-pump. We find that post-translational
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modifications near this binding site regulate substrate recruit-
ment, and that disrupting the zDHHC5-Na-pump interaction
reduces palmitoylation of the zDHHC5 substrate PLM. Hence we
demonstrate the selective pharmacological targeting of a palmi-
toylated protein by interfering with its recruitment to a zDHHC-
PAT.
The Na-pump binding site on zDHHC5 is located distal to the
enzyme active site and contacts the third intracellular loop (IL3,
αα 339–772) of the Na-pump α subunit. This interaction correctly
positions PLM within the zDHHC5 active site, where it becomes
palmitoylated. However, this does not rule out the possibility of
zDHHC5 and the Na-pump α-subunit interacting indirectly via
an adapter protein. Recently the activity and localization of
zDHHC5 in HEK and HeLa cells has been found to be regulated
by two closely related proteins, Golga747 and Golga7b23 respec-
tively. Golga7b is palmitoylated by zDHHC5 and interacts with
the same region of the zDHHC5 C tail as the Na-pump in a
palmitoylation-dependent manner. Palmitoylated Golga7b is
required for delivery of zDHHC5 to the cell surface as well as
recruitment to and palmitoylation of substrates by zDHHC523.
When we carried out a detailed proteomic analysis of the proteins
in cardiac muscle that interact with NBSP, however, neither
Golga7 nor Golga7b were identified48. Therefore, if an adapter
protein is required to mediate the interaction between zDHHC5
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Fig. 5 Selective pharmacological manipulation of PLM palmitoylation. a HEK cells stably expressing human PLM were incubated with 30 µM of a
stearate-tagged peptide (either NBSP (DP) or scrambled NBSP (S)) for a period of 3 or 24 h. Following cell lysis, relative PLM and Ras palmitoylation
(Palm/UF) values were determined using a combination of Acyl-RAC and Western Blotting (PLM: n= 6; Ras: n= 4; **p < 0.01, ****p < 0.0001). b The
same treatments were also applied to adult rat ventricular myocytes prior to determining the palmitoylation status of both PLM and Cav3 (PLM: n= 6;
Cav3: n= 4; *p < 0.05).
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and the Na-pump in the heart, it is unlikely to be either Golga7 or
7b but rather an as yet unidentified protein of novel function.
A major finding of our work is the observation that covalent
modification (both palmitoylation and GlcNAcylation) of residues
proximal to a substrate-binding site on a zDHHC-PAT affected
both the recruitment and palmitoylation of that substrate—a
phenomenon that will likely apply to many other zDHHC-PATs
and enzyme-substrate combinations. Regulation of substrate
recruitment by palmitoylation of cysteine residues in the zDHHC5
C-tail has previously been postulated by Yang and co-workers37,
and is now confirmed here. The C-terminal regions of all zDHHC-
PATs contain one or more cysteines suggesting that substrate
recruitment to zDHHC-PATs may commonly be regulated by site-
specific palmitoylation. Our studies also revealed the existence
of a palmitoylation cascade with zDHHC20 acting upstream of
zDHHC5. The ER-resident zDHHC-PAT zDHHC6 is palmitoy-
lated by zDHHC16 at three cysteine residues located within a SH3
binding domain at the enzyme’s C-terminus49. It would, therefore,
seem likely that palmitoylation cascades are a common regulatory
feature of zDHHC-PAT activity also.
Palmitoylation of the cardiac sodium/calcium exchanger
(NCX1) is determined by the presence of a juxtamembrane
amphipathic helix located next to the cysteine residue that gets
modified50. By analogy, it is possible that palmitoylation at the
dicysteine motif on zDHHC5 by zDHHC20 is facilitated by the
zDHHC5 amphipathic helix, with specificity for zDHHC20
determined by the chemical properties of the side chains pro-
truding from the hydrophilic face of the helix (as is the case for
NCX1). Palmitoylation of the ubiquitin ligase GobX by
zDHHC20 is also dependent on an amphipathic helix proximal to
the palmitoylated cysteine51. In contrast, the zDHHC20 palmi-
toylation sites in the epidermal growth factor receptor lie in an
unstructured part of its C tail52.
In contrast to the relationship between some zDHHC-PATs
and their substrates53, the interaction between zDHHC5 and the
Na-pump was sufficiently tight to enable their co-purification in
complex with each other. One question arising from this obser-
vation is by what means is the Na-pump released from zDHHC5
following palmitoylation of PLM? We anticipate that the sub-
strate release is driven by the energetic requirement of the fatty
acid attached to PLM to reside within a hydrophobic membrane
rather than aqueous solution. We speculate that incorporation of
the fatty acid within the lipid bilayer will induce conformational
changes within the Na-pump, PLM in particular, that result in
release of the pump from zDHHC5.
Specific manipulation of protein palmitoylation with small
molecules for use in the clinic is highly desirable but currently
remains out of reach54. To date, efforts to discover inhibitors of
zDHHC-PATs have exclusively focussed on the enzyme’s active
site as the catalytic pocket is considered to be druggable. Even if
isoform-specific active site inhibitors could be identified, how-
ever, they are unlikely to be therapeutically useful as they would
block palmitoylation of the entire substrate ensemble of the
zDHHC-PAT(s) on which they act, not just the protein of
interest. The data presented here, however, suggests that in future
it may be possible to develop molecular modulators of protein
palmitoylation that act by selectively blocking or enhancing the
recruitment of particular substrate proteins to their cognate
zDHHC-PAT(s). For example, a molecule that prevented
recruitment of the Na-pump to zDHHC5 would block PLM
palmitoylation increasing the pump’s activity, and would be
useful for treating heart failure and cardiac hypertrophy31.
Molecules that target substrate binding sites on zDHHC-PATs
themselves may suffer from a lack of selectivity if several sub-
strates bind to the enzyme in the same region. For example, the
disruptor peptide used here may also alter the palmitoylation
status of other proteins that interact with the NBSP region of
zDHHC5. In contrast, molecules that interact with the substrate
itself blocking or enhancing its interaction with (a) zDHHC-PAT
(s) offer better promise. Protein S-palmitoylation is associated
with a wide-range of cancers52,55–60, and can be hijacked by
pathogens61,62. Through understanding how individual proteins
are recruited to their partner zDHHC-PAT(s), it should be pos-
sible to develop screening strategies that will enable the identifi-
cation of molecules that selectively alter the palmitoylation status
of particular proteins that can ultimately be developed into
therapeutic drugs for use in the clinic to treat a wide-range of
diseases.
Methods
Ethics statement. This study utilized primary ventricular myocytes from male
Wistar rats (250–300 g, 7–9 weeks). All protocols involving animals were approved
by the Animal Welfare and Ethics Review Boards at the Universities of Dundee and
Glasgow. Rat cardiac tissues were collected postmortem after sacrificing animals
using a method designated Schedule 1 by the Animals (Scientific Procedures)
Act 1986.
Antibodies and chemicals. All chemicals were of the highest grade available and
were purchased from Sigma–Aldrich unless indicated otherwise. All HEK cell
transfections utilized Lipofectamine 2000 (ThermoFisher Scientific). Primary
antibodies were from the following sources: PLM phospho-S68—custom made38,
zDHHC5—Sigma–Aldrich HPA014670 (diluted 1:2000 for western blots), Flotillin
2—BD Biosciences 610383 clone 29 (1:2000), PLM—Abcam ab76597 (1:2000), HA
tag—Roche, clone 3F10 (1:2000), FLAG—Sigma F1804 clone M2 (1:2000),
Caveolin 3—BD Biosciences 610421 clone 26 (1:5000), sodium pump α1 subunit,
Development Studies Hybridoma Bank, clone α6F (1:100), Ras—Merck 05-516,
clone RAS10 (1:2000). HRP-linked secondary antibodies were from ThermoFisher
Scientific (antirat, diluted 1:2000 for western blots) and Jackson ImmunoResearch
(antirabbit and antimouse, both diluted 1:2000 for western blots). Western Blots
utilized Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore,
Watford, UK) and were visualized and analyzed using a ChemiDoc XRS acquisi-
tion system running QuantityOne software (BioRad).
zDHHC5 peptide array. An array of 25 amino acid peptides overlapping by 15
residues each, representing the C tail of rat zDHHC5 was purchased from Alta
Bioscience. Each peptide had an N terminal biotin for affinity purification. Rat
ventricular lysates were precleared by incubation with streptavidin Sepharose (GE
Life Sciences) for 1–2 h at 4 °C, incubated with 1 μg peptide (~0.2 μM final con-
centration) overnight at 4 °C with end-over-end mixing, and the peptides purified
the next day with streptavidin Sepharose. After extensive washing peptide–protein
complexes were eluted with SDS PAGE loading buffer.
Plasmids and transfections. Plasmids encoding HA-tagged murine zDHHC
isoforms were generously provided by Masaki Fukata, Division of Membrane
Physiology, National Institute for Physiological Sciences, Okazaki, Aichi, Japan.
HEK-derived FT-293 cells constitutively expressing human PLM were
generated using the Invitrogen Flip-In system. All transfections of plasmid DNA
used Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
Site-directed mutagenesis. All point mutants were generated using the Quik-
Change II site directed mutagenesis kit (Agilent). Mutagenesis primers were
designed using the QuickChange primer design online tool provided by Agilent,
and purchased from ThermoFisher Scientific. Mutagenesis primers were zDHHC5
C236/7AA: forward—tgaatcccttcaccaatggcgccgctaacaacgttagccgtgtcc, reverse—gga-
cacggctaacgttgttagcggcgccattggtgaagggattca; zDHHC5 S241A: forward—
ccaatggctgctgtaacaacgttgcccgtgtcctctg, reverse—cagaggacacgggcaacgttgtta-
cagcagccattgg; zDHHC5 C245A forward—gttagccgtgtcctcgccagttctccagcacc, reverse—
ggtgctggagaactggcgaggacacggctaac; zDHHC20 C156S (zDHHS20) forward—tcttaa-
gatggatcatcacagtccatgggtgaataactg, reverse—cagttattcacccatggactgtgatgatccatcttaaga.
Immunoprecipitation and pulldown experiments. We used anti HA affinity
matrix (Roche) to immunoprecipitate HA tagged proteins from cell lysates as
described previously13.
GST fusion proteins of the Na-pump third and fourth intracellular loops
(human isoform: IL3 (αα 339–772), IL4 (αα 824–843) were expressed in E. coli
strain BL21(DE3) and purified using a 5 ml glutathione column (GE Healthcare).
Following desalting into PBS, the recombinant proteins were incubated overnight
with HEK cell lysates that had been prepared in PBS supplemented with 2 mg/ml
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C12E10 and protease inhibitors. The following day, interacting proteins were
captured by pulling down with glutathione sepharose beads (GE Healthcare).
Halo-tagged catalytically inactive (D298N) O-GlcNAcase (OGA) from
Clostridium perfringens was used to purify GlycNAcylated proteins from HEK cell
and ventricular myocyte lysates via HaloLink agarose (Promega) in RIPA buffer
(50 mM Tris pH 7.5, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM
NaCl, 2 mM EDTA, 50 mM sodium fluoride)63. After extensive washing (50 mM
Tris pH 7.5, 0.02% TWEEN 20, 450 mM NaCl) captured proteins were eluted by
incubating the beads for 45 min at 4 °C with wash buffer supplemented with 2 mM
Thiamet G.
Adult rat ventricular myocytes. Calcium-tolerant adult rat ventricular myocytes
were isolated by retrograde perfusion of collagenase in the Langendorff mode.
Myocytes were plated onto laminin coated culture dishes before experimentation.
Resin assisted capture of acylated proteins. Acylated proteins were purified
using thiopropyl Sepharose (GE Life Sciences) in the presence of neutral hydro-
xylamine from cell lysates in which irrelevant cysteines had first been alkylated
with S-Methyl methanethiosulfonate38,39. The palmitoylation status of all our
proteins of interest were determined by measuring their abundance in the acyl-
RAC purified fraction relative to that in the starting (unfractionated) cell lysate.
Acyl PEG exchange. We used a refinement40 of our acyl PEG switch assay13 that
PEGylates previously palmitoylated cysteines following removal of hydroxylamine.
Irrelevant cysteines in cell lysates were blocked using 100 mM maleimide. Excess
unreacted maleimide was removed by acetone precipitation, and previously pal-
mitoylated cysteines were revealed by treatment with 250 mM neutral hydro-
xylamine for 1 h at room temperature. Lysates were desalted using Zeba spin
columns (ThermoFisher Scientific) and incubated with 2 mM 5 kDa methox-
ypolyethylene glycol maleimide for 1 h at room temperature. The reaction was
quenched with SDS PAGE loading buffer supplemented with β-mercaptoethanol,
and analyzed directly by SDS PAGE.
zDHHC5 knockout cells. We used guide RNAs (gRNA) targeted against zDHHC5
provided by Horizon Discovery to generate zDHHC5 knockout HEK cells64.
Identification of biotinylated zDHHC5 interacting proteins. HEK cells in
10 cm dishes were transfected with pcDNA3.1 mycBioID, pcDNA3.1 BirA-HA,
pcDNA3.1 BirA-zDHHC5, and pcDNA3.1 zDHHC5-BirA and maintained over-
night with 50 μM biotin. The next day after extensive washing cells were lysed in
0.1% SDS, 1% Triton X-100 in PBS supplemented with protease inhibitors, inso-
luble material removed by centrifugation, and biotinylated proteins captured using
streptavidin Sepharose overnight at 4 °C. Beads were washed five times with 0.1%
SDS, 1% Triton X-100 in PBS, then five times with 1M urea in 100 mM ammo-
nium bicarbonate. Biotinylated proteins were digested with Trypsin Gold (Pro-
mega) in 1 M urea in 100 mM ammonium overnight at 37 °C, then reductively
alkylated and analyzed using a LTQ Orbitrap Velos Pro (Thermo) at the Finger-
Prints Proteomics Service, University of Dundee. Mascot reports including peptides
identified are provided in Supplementary Data 1.
Stearate-tagged disruptor peptides. Peptides with a N terminal stearate group
and a C-terminal Biotin were manufactured by DC Bioscience. Disruptor peptide:
stearate-TNGCCNNVSRVLCSSPAPRYLGRPK-Biotin; scrambled: stearate-
LSAYNTVNRRCSKGRVPNCGPCSPLK-Biotin.
Statistics and reproducibility. Quantitative data are presented as means ± S.E.
Differences between experimental groups were analyzed by one-way analysis of
variance followed by post-hoc tests using Graphpad Prism. Differences were
considered statistically significant when p was <0.05.
No data was excluded from any analysis and all experiments were reproducible.
In all cases sample sizes refer to biological replicates, which were defined as
independently prepared, biologically distinct samples.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Reagents and datasets generated and analysed during the current study are available from
the corresponding authors on reasonable request. Uncropped Western blots and source
data sets are available in the Supplementary Information and Supplementary Data 4,
respectively.
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